This K23 Mentored Patient-Oriented Career Development Award application is to request support for Dr. Dalrymple's development as an independent investigator specializing in combined treatment trials (psychotherapy plus pharmacotherapy) for patients with complicated presentations of depression. The short- term goal of this award is to develop and evaluate the feasibility and acceptability of a psychosocial intervention to augment pharmacotherapy for patients with comorbid Major Depressive Disorder (MDD) and Social Anxiety Disorder (SAD), as this comorbidity pattern is highly prevalent yet undertreated in routine psychiatric settings. The training goals of this application include: 1) obtain further experience in treating this population by developing an integrated behavioral treatment;2) receive training in the development of psychosocial interventions for MDD;3) obtain training in the pharmacological treatment of MDD and SAD to prepare for future combined treatment trials;4) develop skills in the implementation of treatment research in routine practice settings;5) receive formal training in advanced longitudinal data analytic methods as applied to clinical trials;6) expand grant writing and manuscript preparation skills;and 7) obtain further knowledge of ethical and multicultural issues related to treatment outcome research. These goals will be accomplished through mentorship provided by Drs. Zimmerman and Miller as well as other consultant mentors, completion of coursework, seminars, and clinical experiences, and implementation of the proposed research project. The 5- year research plan will include the development of a psychosocial treatment integrating behavioral and acceptance-based techniques to augment pharmacotherapy for patients with comorbid MDD-SAD, called Depression and Social Anxiety Treatment (DASAT). The goals of this research project are to: 1) develop a treatment manual for DASAT by conducting an initial open trial (n=20);2) conduct a randomized controlled pilot study comparing pharmacotherapy-as-usual (PAU;n=15) to pharmacotherapy-as-usual plus DASAT (PAU+DASAT;n=15), to examine the feasibility and acceptability of the intervention;3) develop a therapist training program;4) develop and test therapist adherence and competence scales;and 5) refine DASAT and study procedures to prepare for a larger clinical trial.

Public Health Relevance

The proposed project will result in substantial public health benefit because it will be developed for and tested in a routine practice setting, where the prevalence of comorbid Major Depressive Disorder and Social Anxiety Disorder is highest and improved treatments for it are needed. In addition, the treatment will target overall functioning and quality of life as well as symptoms, and will be designed to augment pharmacotherapy, further increasing its public health impact.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23MH085730-02
Application #
8012276
Study Section
Interventions Committee for Adult Disorders (ITVA)
Program Officer
Wynne, Debra K
Project Start
2010-01-15
Project End
2014-11-30
Budget Start
2010-12-01
Budget End
2011-11-30
Support Year
2
Fiscal Year
2011
Total Cost
$149,586
Indirect Cost
Name
Rhode Island Hospital
Department
Type
DUNS #
075710996
City
Providence
State
RI
Country
United States
Zip Code
02903
Dalrymple, Kristy L; Morgan, Theresa A; Lipschitz, Jessica M et al. (2014) An Integrated, Acceptance-Based Behavioral Approach for Depression With Social Anxiety: Preliminary Results. Behav Modif 38:516-48
Kelly, Megan M; Dalrymple, Kristy; Zimmerman, Mark et al. (2013) A comparison study of body dysmorphic disorder versus social phobia. Psychiatry Res 205:109-16
Dalrymple, Kristy; Martinez, Jennifer; Tepe, Elizabeth et al. (2013) A clinically useful social anxiety disorder outcome scale. Compr Psychiatry 54:758-65
Zimmerman, Mark; Chelminski, Iwona; Young, Diane et al. (2012) Does the presence of one feature of borderline personality disorder have clinical significance? Implications for dimensional ratings of personality disorders. J Clin Psychiatry 73:8-12
Tepe, Elizabeth; Dalrymple, Kristy; Zimmerman, Mark (2012) The impact of comorbid cannabis use disorders on the clinical presentation of social anxiety disorder. J Psychiatr Res 46:50-6
Zimmerman, Mark; Chelminski, Iwona; Young, Diane et al. (2012) Impact of deleting 5 DSM-IV personality disorders on prevalence, comorbidity, and the association between personality disorder pathology and psychosocial morbidity. J Clin Psychiatry 73:202-7
Zimmerman, Mark; Chelminski, Iwona; Young, Diane et al. (2012) Is Dimensional Scoring of Borderline Personality Disorder Important Only for Subthreshold Levels of Severity? J Pers Disord :
Zimmerman, Mark; Galione, Janine N; Chelminski, Iwona et al. (2012) Does the diagnosis of multiple Axis II disorders have clinical significance? Ann Clin Psychiatry 24:195-201
Zimmerman, Mark; Dalrymple, Kristy; Young, Diane et al. (2012) An Empirical Examination of Gunderson's Proposed Revision of the Diagnostic Algorithm for Borderline Personality Disorder. J Pers Disord :
Zimmerman, Mark; Young, Diane; Chelminski, Iwona et al. (2012) Overcoming the problem of diagnostic heterogeneity in applying measurement-based care in clinical practice: the concept of psychiatric vital signs. Compr Psychiatry 53:117-24

Showing the most recent 10 out of 22 publications